Nonaqueous redox flow batteries are one economically promising solution for meeting grid-scale energy storage needs at discharge durations of 10 h or more. However, membrane transport properties in nonaqueous systems are not as well understood as in water. Solvent-specific effects complicate efforts to understand transport in nonaqueous. In one aspect, the disclosure relates to blended cross-linked membranes compositions, methods of making same, and devices, products, and systems comprising same. In one aspect, the disclosed blended cross-linked membranes compositions comprise a cross-linked first polymer and a second polymer. The disclosed blends have desired permeabilities for selected cations and rejected undesired materials from the redox reaction mixture. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
In some aspects, the techniques described herein relate to a method of processing a photovoltaic module structure including multiple layers, the method including: irradiating the photovoltaic module structure with a laser emission to target a specified layer with the laser emission using a specified wavelength of the laser emission; wherein the irradiating includes at least one of: delaminating at least a portion of the specified layer of the photovoltaic module structure from an adjacent layer amongst the multiple layers; or repairing a defect in the specified layer photovoltaic module structure; or both.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
4.
VIBRATION BASED INTERACTION SYSTEM FOR ON BODY DEVICE AND METHOD
Disclosed are various embodiments for recognition of on body touch interactions and gestures using an on-body device. A sample of vibration data from the vibration sensor is input into a trained convolutional neural network. The vibration data is generated from a vibration event. In response, the trained convolutional neural network outputs one of a plurality of predefined vibration event descriptors. The trained convolutional neural network is adapted based at least in part on a plurality of Siamese contrastive loss calculations. Each Siamese contrastive loss calculation is generated from a corresponding pair of preexisting samples of vibration data from a pool of preexisting samples of vibration data.
Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and/or derivatives thereof and/or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and/or for preparing medicaments therefore.
A computerized system calculates a composite index for sets of functional movement scores that quantify motor function abilities for patients. Wearable sensors, kinetic energy sensors, ultrasound imagers, and force sensors are used to store the composite index from predictors of the functional movement scores, the predictors comprising a respective shape of motion factor, a respective motion symmetry factor, and a respective motion speed factor for each of the sets of functional movement scores. The software tabulates the respective composite index by calculating a probability that the respective shape of motion factor, the respective motion symmetry factor, and the respective motion speed factor correspond to one of the sets of functional movement scores.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity, including against multidrug-resistant bacteria. In some embodiments, the peptides include amino acid sequences as set forth in any of SEQ ID NOs: 2-151, modified peptides, fragments, and conjugates thereof, and any combination thereof. The peptides, modified peptides, fragments, and conjugates can be polymer- functionalized, encapsulated in a particle, embedded in and/or on a solid support, impregnated in a dressing, and/or is formulated for use in a nebulizer, for topical administration, and/or for systemic administration. Also provided are medical devices having an antibacterial agent embedded in and/or associated with a support layer, and methods for inhibiting growth of and/or killing bacteria, for treating or preventing community and/or nosocomial infections, for treating bacterial infections present in wounds, for treating pulmonary infections, for treating or preventing systemic bacterial infections, and for combination therapies with conventional antibiotics.
UNIVERSITY OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (IMHR) (Canada)
Inventor
Payne, Jennifer
Kaminsky, Zachary
Abstract
The present invention relates to the field of Premenstrual dysphoric disorder (PMDD) and perimenopausal depression (PMD). More specifically, the present invention relates to the use of biomarkers to diagnose PMDD, PMD or predict a risk thereof. In one embodiment, a method for identifying a likelihood of PMDD and/or PMD in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring white blood cell type counts and DNA methylation levels of a panel of biomarkers or using a proxy marker to estimate the ratio monocytesmon-monocytes in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B and the white blood cell type counts comprise monocytes and non-monocytes; and (c) using a linear model that utilizes the DNA methylation level of HP1BP3 and TTC9B and the ratio of monocytesmon-monocytes or proxy marker to determine the patient is likely to develop PMDD and/or PMD.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
10.
MICROFLUIDIC SYSTEM AND METHOD FOR DNA METHYLATION SAMPLE PREPARATION
Various aspects disclosed relate to a centrifugal microfluidic device to perform dynamic solid phase sodium bisulfate conversion. The device includes a reaction assembly. The reaction assembly includes a plurality of individual chambers, each including a bisulfate conversion chamber, an elution chamber, a magnetic manipulation chamber, a waste chamber, and a buffer chamber. The reaction assembly further includes at least one valve configured to selectively establish or prevent fluid communication along a channel between at least two respective individual chambers amongst the plurality of individual chambers. Additionally, the reaction assembly is configured to establish fluidic transport in response to rotation about an axis intersecting a central region of the reaction assembly and perpendicular to a plane on which the reaction assembly is disposed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
UNIVERSITY OF VIRGINIA PATENT FOUNDATION (USA)
Inventor
Capobianco, Joseph, A.
Lee, Joseph
Chen, Chin Yi
He, Yiping
Armstrong, Cheryl, M.
Reed, Sue, A.
Berger, Bryan
Abstract
Provided herein are compositions and methodologies for identifying microbes in biofilms and adhered to biotic and abiotic surfaces, utilizing enzymes that degrade biofilms and disperse aggregated clusters of microorganisms. Utilizing enzymes such as CAase to degrade biofilms, organisms released from biofilms are identified more readily than from untreated biofilms. Biofilms from a variety of sources, both biotic and abiotic, can be analyzed utilizing the present disclosure.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
12.
COMPOSITIONS COMPRISING LINEAR, STAR-SHAPED, AND COMB-LIKE STAPLED P9-PEG CONJUGATES AND METHODS OF USE THEREOF
Provided are stapled peptides and conjugates thereof that have antibacterial activity against microbial pathogens that include, but are not limited to, multidrug-resistant bacteria. Also provided are stapled peptides and conjugates thereof that are functionalized, encapsulated in a particle, and/or embedded in and/or on a solid support, optionally wherein the stapled peptide and/or conjugate is formulated for release from the solid support, impregnated in a dressing, optionally wherein the stapled peptide and/or conjugate thereof is formulated for release from the dressing, medical devices having a support layer with an antibacterial agent embedded therein or associated therewith, and methods for inhibiting the growth of and/or killing microbes.
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
C07C 67/04 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides onto unsaturated carbon-to-carbon bonds
C07C 69/22 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
14.
BIOMIMETIC TORPEDO FOR STENT-FREE AND TARGETED GENE THERAPY TO PREVENT RESTENOSIS
Disclosed herein is a biomimetic torpedo that can circumvent existing hurdles for RNA therapies. That is, RNA therapeutics can be harbored inside a torpedo shell made of neutrophil membranes in hybrid with a liposome membrane, which enables lesiontargeting and shielding from immunogenicity. Further disclosed herein is a biomimetic targeting system that involves a neutrophil cell membrane capsule that encapsulates a therapeutic RNA.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
The present disclosure provides for methods of making graphene, systems for making graphene and graphene produced from the methods and systems. Biomass materials, such as cotton materials, can be converted to graphite and then the graphite is converted into graphene. One method of the present disclosure can include removing substances from the biomass material, carbonization, graphitization, and exfoliation.
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing sonic or ultrasonic vibrations
16.
USE OF LASERS TO SELECTIVELY REMOVE MATERIALS FROM SUBSTRATES
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein are methods for selectively removing a material from a surface of a substrate. The method involves applying a laser to the material to remove the material from the substrate. The laser thermally vaporizes the material or de-bonds the material from the substrate to produce particles, and the material particles can be subsequently removed and re-used in subsequent applications. The methods described herein provide an efficient process for removing materials from substrates that would otherwise be discarded.
B23K 26/122 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure in a liquid, e.g. underwater
B23K 26/082 - Scanning systems, i.e. devices involving movement of the laser beam relative to the laser head
B23K 26/16 - Removal of by-products, e.g. particles or vapours produced during treatment of a workpiece
B23K 26/50 - Working by transmitting the laser beam through or within the workpiece
C04B 41/91 - After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone of only ceramics involving the removal of part of the materials of the treated articles, e.g. etching
H01L 27/14 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy
17.
MICROTEXTURIZED SUBSTRATES AND METHODS FOR PRODUCING THE SAME
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to methods for producing a microtextured surface on a substrate. The method involves the surface of the substrate to a pulsed laser across the substrate at a controlled overlap of each pulsed laser to produce the microtextured surface. The morphology of the microtextured surface can be varied by controlling the laser processing parameters. The microtextured surfaces produced by the methods described herein possess a significantly higher adhesion strength to surface coatings such as, for example, metal coatings when compared to conventional texturizing techniques.
Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron- emitting mannitol analogue, [18F]fluoromannitol ([18A. baumanniiS. epidermisP.mirabilisS. entericaK. pneumonia,E. faecium E. cloacaeM. marinumM. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.
In one aspect, the disclosure relates to methods for producing hydrophobic or superhydrophobic surfaces on an article. The method involves laser depositing hydrophobic materials on at least one surface of the article. By varying the laser parameters as well as the surface of the where the hydrophobic material is to be laser deposited, the hydrophobic properties of the surface can be modified. The starting substrate could be hydrophilic or superhydrophilic.
C03C 17/30 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
C03C 17/28 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with organic material
C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
Compositions, foodstuff and methods are provide herein from cereal plant or a part thereof, wherein the plant or part thereof has an altered (I,3;l,4)-p-glucan content as compared to a wild-type cereal plant or part thereof, wherein said, plant or part thereof carries one or more mutations in the CslF6 gene, wherein said mutated. CslF6 gene encodes a mutant CslF6 polypeptide, wherein said mutant CslF6 comprises at least one substitution, addition or deletion of an amino acid in a switch motif of CslF6, wherein the switch motif comprises SEQ ID NO: 14.
A microfluidic system can be used to quantify apoptotic bodies (ABs) with single-cell sensitivity, providing real-time information regarding the presence, and properties of ABs. Different subpopulations of ABs can thus be distinguished from one another to quantify cellular dis-assembly and drug sensitivity of the cancer cells under test. Impedance measurement can be performed by flowing secreted bodies at a substantially single-particle sensitivity. A plurality of electrical impedance magnitude and phase parameters of the biological sample can be measured within the flow cell structure, corresponding to a specified range of frequencies to help determine a biological characteristic of the cancer cells.
A method of automated cell culturing and characterization can include regulating one or more parameters of an ambient environment within an environmentally isolated, airtight enclosure. A biological specimen can be cultured within the enclosure, e.g., including aspirating and dispensing, via an automated fluid handling system having a fluidic interface disposed within the airtight enclosure, a portion of the biological specimen. The dispensing can be into a first vessel, e.g., by suspending individual cells of the portion of the biological specimen within a microcarrier matrix contained by the first vessel and exposed to the ambient environment within the airtight enclosure.
Embodiments relate to a database management system for efficient physiological diagnosis of a specified physiological disorder. The system includes a physical data store containing glucose measurement data and a representation for a classification of the glucose measurement data. The glucose measurement data is associated with controlled glycemic-response consumption activity, the representation being indication that a glucose measurement trace is associated of a specified physiological disorder or is indicative of the specified physiological disorder, or is a surrogate of an existing metabolic test, e.g. OGTT. A processor receives a new glucose measurement possibly associated with controlled glycemic-response consumption activity, and classifies the newly received glucose measurement trace with the representation based either on a disease- or test-specific classifier or based on a matched similarity metric, and ascribes a clinical recommendation or assessment based on the representation of the classified newly received glucose measurement trace.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
According to some embodiments, a linear-reversible-linear (LRL) copolymer may comprise an A(BC)A triblock copolymer. The A(BC)A triblock copolymer may comprise an A block and a BC block. The A block may a linear polymer and the BC block may comprises a copolymer with the ability to form reversible bonds. Further embodiments include methods of making and methods of using the LRL copolymer.
C08F 220/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
25.
METHOD AND SYSTEM FOR ALL-AQUEOUS PRINTING OF VISCOELASTIC DROPLETS
This document describes printing viscoelastic material in an aqueous medium. Such printing can involve positioning a print nozzle at specified coordinates in the medium and triggering deposition of the viscoelastic material to form a viscoelastic droplet. The deposition can be established by delivering a specified flow velocity of the viscoelastic material through an aperture in the print nozzle. The print nozzle can be detached from the droplet and a receiving material by translating the nozzle relative to the droplet according to a specified acceleration. The droplet can remain captive on or within the receiving material upon detachment from the nozzle.
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
26.
MEASUREMENT OF PERMEATION OF SMALL MOLECULES INTO GRAM NEGATIVE BACTERIA
Disclosed herein are processes term Bacterial Chloro-Alkane Penetration Assay (BaCAPA) and Bacterial Azide Permeability Assay (BAPA) The processes employ a genetically encoded protein called HaloTag to measure the uptake and accumulation of molecules into Gram-negative bacteria. The processes aqre useful in assessing the permeation of molecules within the phagocytes of macrophages, and they effectively report on the accumulation of molecules into bacterial cells, thereby identifying potential antibiotic drugs.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
C12Q 1/18 - Testing for antimicrobial activity of a material
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups
27.
DEVELOPMENT OF NANO-ENCAPSULATED FATTY-ACYL CONJUGATED COLCHICINE
Provided are compositions that include colchicine conjugated to behenic acid, optionally wherein the colchicine conjugated to behenic acid is encapsulated by a nanoliposome. In some embodiments, the colchicine is conjugated to behenic acid at the acetamide position of a B-ring of colchicine, the nanoliposome includes a lipid component comprising DSPC, DOPE, and DSPE-PEG, and cholesterol; and/or the colchicine conjugated to behenic acid is present in the nanoliposome in an amount of at least about 400, 500, 600, or more than 600 pg/mL. Also provided are methods for preparing behenic acid-conjugated colchicine derivatives, methods for preparing lipid nanoparticle-encapsulated colchicine derivatives, and methods for using the same to treat and/or prevent inflammatory and/or cardiovascular diseases, disorders, and/or conditions.
Provided are compositions that include compositions of galactosyl-conjugated lipid, nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl-conjugated LNPs have a lipid component having D-Lin-MC3 -DMA, ALC-0315 and SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalN Ac-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc-conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with undesirable gene expression and methods for targeting active agents to hepatocytes using the presently disclosed GalN Ac-conjugated LNPs.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
29.
SYSTEM AND METHOD FOR IDENTIFYING CLINICALLY-SIMILAR CLUSTERS OF DAILY CONTINUOUS GLUCOSE MONITORING (CGM) PROFILES
Embodiments relate to a system for processing glucose data by efficient glucose database management. The system includes a physical data store containing glucose measurement data and a representation for at least one cluster of the glucose measurement data, wherein the representation approximates a glycemic profile vector array for a cluster of multiple glucose profiles segmented by plural time ranges. The system includes a processor and computer memory configured with instructions stored thereon that when executed will cause the processor to: 1) receive glucose measurements; 2) convert the glucose measurements into vectorial form; 3) search the physical data store by comparing a newly received glucose measurement to a centroid of a cluster using a similarity metric; 3) classify the newly received glucose measurement with a cluster having a matched similarity metric based on the comparing; and 4) ascribe a treatment to the newly received glucose measurement.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Provided are composition that include stable TLR4 agonist (e.g., KDO2) containing nanoliposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome include a lipid component comprising, consisting essentially of, or consisting of DSPC, DOPE, PEG(2000)-PE, one or more TLR4 agonists (e.g., KDO2), Cholesterol, Rhodamine or DiD, and optionally DOTAP and/or DHP. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposomes are cationic, anionic, or neutral liposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome encapsulate one or more immunogenic peptides, which can be peptides associated with malignant melanoma, which optionally can be subsequences of tyrosinase, gplOO, MAGE-1,2,3,6, Melan-A/MART- 1, and/or MAGE-3. Also provided are methods for treating and/or preventing malignant melanoma and for inducing anti-melanoma immune responses in subjects using the presently disclosed compositions.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
In some examples, method for automatically computing a blood input function for dynamic positron emission tomography (PET) includes obtaining dynamic PET image data sets comprising volumetric radioactive measurement data associated with an administered radioactive tracer present in a target site of a subject over multiple scanning intervals. The method includes utilizing an artificial neural network (ANN) to segment the dynamic PET image data sets displaying one or more blood vessels in the target site. The method includes automatically deriving, using the ANN, a blood input function ( I D I F) based on radioactive tracer concentrations measured in one or more segments of the plurality of dynamic PET image data sets. The method includes computing a predictive model-corrected blood input function (MCIF) using time activity curve input associated with the automatically derived IDIF.
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
Boronated prodrugs have been developed that are particularly advantageous for use in boron proton capture therapy (BPCT) and boron neutron capture therapy (BNCT). Cancer-targeting moieties, such as heptamethine cyanine dyes (HMCDs), are linked to compounds including a plurality of boron isotopes, e.g., carboranes such as 1 -amino- 1-carbadodecaborate. Compounds of the present disclosure were demonstrated to deliver eleven boron-11 atoms per dye molecule selectively to breast cancer cells. Upon irradiation with proton or neutron beams and subsequent nuclear fusion reaction by proton capture, unstable 12C is generated in place of 11B, which is short lived and releases high energy alpha particles. There particles travel only a short distance within cell and/or a very close tumor microenvironment, damaging cellular DNA ultimately resulting in killing cancer cells, and are particularly useful with young patients and with deep tissue tumors located in critical organs which are difficult to remove by surgery.
Provided are compositions and methods for treating cancer and mimicking oxidative stress in a subject. In some embodiments, the methods include modulating vascular oxidative stress, inflammation, and/or hypertension in a subject. Also provided are methods for evaluating therapeutic compositions in a subject with modulated vascular oxidative stress, inflammation, and/or hypertension.
Provided are methods for identifying subjects at risk for reduced lifespan, age- associated cardiomyopathy, reduced cardiac function, heart failure, increased fibrosis of the myocardium, lung, and/or kidney; idiopathic pulmonary fibrosis (IPF); elevated left ventricular filling pressure (E/e') indicative of diastolic dysfunction; and/or reduced cognitive function. In some embodiments, the methods include determining if the subject has mosaic loss of chromosome Y in blood (mLOY). Also provided are methods for preventing and/or treating diseases, disorders, and/or conditions associated with mLOY, which in some embodiments also include administering an anti-fibrotic therapy to the subject. Also provided are uses of inhibitors of TGF0 signaling or senolytic agents for prevention and/or treatment of diseases, disorders, and/or conditions associated with mLOY.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6865 - Promoter-based amplification, e.g. nucleic acid sequence-based amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
C12Q 1/6879 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
36.
DELIVERY OF DISSOCIATED ISLETS CELLS WITHIN MICROPOROUS ANNEALED PARTICLE SCAFFOLD TO TREAT TYPE 1 DIABETES
Provided are compositions that include single cell suspensions of pancreatic islet cells, pancreatic islet-like cells derived from iPS cells, or combinations thereof, wherein the cells are present within a MAP scaffold and/or are encapsulated by MAPs. In some embodiments, the MAP scaffold and/the MAPs have a polymer backbone that includes poly(ethyleneglycol) (PEG), hyaluronic acid, polyacrylamide, polymethacrylate, alginate, collagen, or any combination thereof. Also provided are methods for using the presently disclosed compositions for treating Type 1 diabetes, for example by administering to a subject with Type 1 diabetes such a composition via a route and in an amount effective for treating the Type 1 diabetes in the subject. In some embodiments, the administering includes injecting the composition into a kidney capsule, subcutaneously, intraperitoneally, into adipose tissue, intramuscularly, intrahepatically, and/or intrapancreatically into the subject.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
The invention relates to inhibitors of EWS-FLI1, pharmaceutical compositions containing the inhibitors, and methods of treating cancer, including Ewing sarcoma, leukemia, diffuse large B-cell lymphoma (DLBCL), and prostate cancer, comprising the administration of the inhibitors and pharmaceutical compositions thereof.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 35/02 - Antineoplastic agents specific for leukemia
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
39.
COMBINATION SODIUM-GLUCOSE COTRANSPORTER INHIBITOR (SGLTI)- INSULIN THERAPY FOR GLYCEMIC CONTROL IN TYPE 1 DIABETES
Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).
Disclosed are compositions and methods for treating a disease and/or disorder such as cancer in a subject in need thereof. In some embodiments, the method includes administering to the subject a nucleic acid construct that includes a first nucleic acid sequence having a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by stress-activated kinase activity in a target cell and/or tissue. In some embodiments, the target cell and/or tissue is a cell and/or tissue undergoing a stress response. In some embodiments, the kinase activity is stress-activated kinase activity mediated by p38/MAP14 kinase activity, INK activity, or both.
Hepatocellular cancer (HCC) is the most common primary hepatic malignancy and is the third-highest cause of cancer-related death. Surgical resection and liver transplantation are curative treatments for only a small number of early-stage patients. Disclosed are compositions and methods of treating hepatocellular cancer. The compositions include a combination therapy including nanoliposome C6-cerarnide and anticytotoxic T-lymphocyte antigen 4 antibody.
A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Apparatus and techniques described herein can include or use a rotationally-driven microfluidic assembly. For example, a sample can be propelled to a sample recovery chamber from a sample chamber using a gas evolved from a reaction between the liquid reagent and a dry reagent. Such gas evolution can provide displacement of a sample liquid or other liquid in an inward direction, such as proximally toward a center of rotation. Such gas evolution can include features or reagents, or both, that are compatible with downstream nucleic acid amplification tests.
Provided are methods and compositions for treating and/or preventing C. difficile infections, particularly recurring C. difficile infections. The compositions for use in treating and/or preventing C. difficile infections include in some embodiments at least one agent that inhibits an alpha 2 adrenergic receptor, and the presently disclosed methods include administering at least one such composition to a subject in need thereof, optionally in combination with other therapeutically active agents including but not limited to an enhancer of an IL-13 biological activity, optionally an IL-13 peptide or a fragment or homolog thereof; an interleukin-13 receptor subunit alpha-2 (IL-13Ra2) inhibitor; an enhancer of an Interleukin-33 (IL-33) biological activity, optionally an IL-33 polypeptide or a biologically active fragment or homolog thereof; or any combination thereof.
A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
45.
BUFFER EXCHANGE OF BIOLOGICAL SAMPLES IN-LINE WITH SEPARATION AND MEASUREMENT OPERATIONS
A method can include receiving a biological sample including the target cells, e.g., at an inlet of a microfluidic structure. This can involve flowing the target cells, e.g., suspended in a first buffer, at a first flow rate within a main channel of the microfluidic structure. At least one focusing flow can be applied to the biological sample, using a second buffer at a second flow rate, to help establish a boundary defining a central region or streamline. The central region can contain the target cells within the main channel and promote ion diffusion between the first and second buffers.
Inline classification of a biological specimen including mammalian cells can include generating an alternating current (AC) electrical stimulus to an electrode structure. The electrode structure can be electrically coupled with a flow cell. A response, elicited by the electrical stimulus, can be received when a model specimen class traverses the flow cell. Using the received response, a corresponding impedance parameter value can be determined, the value indicative of a specified biophysical characteristic corresponding to the model specimen class. The first impedance parameter can be translated to a value corresponding to the specified biophysical characteristic.
Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.
THE ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (Australia)
Inventor
Eaton, Miller, Thomas
Gonzalez-Arciniegas, Carlos
Pfister, Olivier
Alexander, Rafael
Menicucci, Nicolas
Abstract
Methods are disclosed for generating, manipulating, and controlling non-Gaussian quantum states in continuous variable cluster quantum states usable for quantum computing. Some methods can be used to generate, transport, and enlarge Schrödinger-Cat states embedded in the CV cluster quantum state. Some methods can be used to transform Schrödinger-Cat states embedded in the CV quantum cluster state to grid states (such as Gottesman-Kitaev-Preskill states) and enlarge the grid states. In certain embodiments, some of the methods may be used to generate and control non-Gaussian states in macronode cluster quantum states such as cluster states comprising two-mode macronodes.
A system, method, and computer readable medium for creating an optimized Radiation Therapy (RT) treatment plan that can safely use a significantly higher dose of therapeutic radiation, and subsequently or concurrently using said plan to perform Radiation Therapy. Additionally, a method of treatment for using Radiation Therapy to safely use a significantly higher dose of therapeutic radiation. A system, method, and computer readable medium permits practitioners or users to create Radiation Therapy treatment plans that minimize the radiation doses applied to the most sensitive parts of the immune system. This technique reduces the negative immune-suppressant side-effects of treating cancer with radiation, which in turn allows practitioners to safely apply a higher dose of radiation than the prior art. Use of this technique results in treatment plans that produce significantly better outcomes for patients at no additional cost. Creating an optimized Radiation Therapy treatment plan for treating lung tumors with Stereotactic Body Radiation Therapy (SBRT) is an example of an application of the system, method, and computer readable medium.
A method of forming a lanthanide or transition metal doped metal halide perovskite material whereby the method includes combining a monovalent metal cation-halide compound, a divalent metal cation-halide compound, and a lanthanide or transition metal halide compound in a solvent; evaporating the solvent to form a powder; and annealing the powder to form the lanthanide or transition metal doped metal halide perovskite material. The resultant materials or devices may be applied to various industrial applications or implemented as a scintillator and applied to various industrial applications.
Systems and techniques for compressed air energy storage and regeneration thereof are described herein. A compressor for compressed air energy storage and regeneration thereof can include a housing, a actuator, and a heat exchanger. The housing can define a volume. The actuator can be operable to expand the volume and compress the volume. The heat exchanger can be located at least partially within the housing. The heat exchanger can be configured to compress when the actuator compresses the volume, expand when the actuator expands the volume, and transfer heat with a working fluid.
Provided are expression cassettes that include coding sequences encoding at least one polar amino acid or at least one expression enhancement peptide that includes one or more polar amino acids, a polypeptide of interest, and a bacterial autotransporter β-barrel polypeptide. In some embodiments, the coding sequences are in frame with each other such that transcription and translation of the expression cassette in a host cell produces a fusion protein with the polar amino acid and/or the expression enhancement peptide, the polypeptide of interest, and the bacterial autotransporter β-barrel polypeptide expressed on the surface of the host cell. Also provided are expression vectors and host cells that include the expression cassettes, vaccine compositions based on the presently disclosed compositions, and methods for inducing immune responses, enhancing expression of the polypeptides of interest, for preventing or treating viral infections such as but not limited to coronavirus infections.
C07K 14/31 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
53.
INFUSION OF FRESH IMMUNE EFFECTOR CELLS ARMED WITH MULTISPECIFIC ANTIBODY
A method for treatment of a patient suffering from a cancer, an autoimmune disease, an infection, a neurodegenerative disease or any combination thereof is disclosed. Compositions and uses are also disclosed. The method includes providing fresh immune effector cells (lECs) armed with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh lECs; and administering an effective amount of a composition of cells to the patient, wherein the composition of cells comprises the multispecific antibody bound fresh lECs. The fresh lECs cab comprise a cell selected from the group consisting of peripheral blood mononuclear cells (PBMC), antigen-presenting cells, T cells (optionally fresh Bi Ab armed T cells (FBATs)), NK cells, monocytes, polymorphonuclear neutrophils (PMNs), and any combination thereof. Providing the fresh lECs can comprise isolating fresh lECs from the patient. Arming fresh lECs can be accomplished with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh lECs.
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Provided are tetravalent bispecific antibodies (T-BiAbs) that have a first binding moiety and a second binding moiety, wherein the first binding moiety is a single chain variable fragment (scFv) and the second, binding moiety-7 is a monoclonal antibody, and further wherein the variable light (Vi.) and variable heavy7 (VH) chains of the first binding moiety7 are directly linked as a. single chain to the second binding moiety at the N-terminus or the C -terminus of the light chain or the heavy chain sequence of the second binding moiety. In some embodiments, the first binding moiety binds to a CDS polypeptide and the second binding moiety-7 binds to a tumor-associated antigen. Also provided are T cells armed with the presently disclosed T-BiAbs and methods of using the same for treating tumor and/or cancers, treating diabetes, arming and isolating stem cells, and manufacturing medicaments for these purposes.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
55.
TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS USING NANO POLYMERS OF HISTONE DEACETYLASE INHIBITORS
Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and/or cancers; and methods for inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.
A differential extraction device includes a first fluidic layer, a second fluidic layer, and a valving layer disposed between the first and second fluidic layers and include multiple chambers and microfluidic channels. The valving layer provides the ability to selectively allow and prevent flow between various chambers. Reagent chambers deliver reagent to a sample chamber and multiple recovery chambers receive material from the sample chamber. The valving layer provides the ability to selectively allow and prevent flow between various chambers.
A system for increasing power capture comprising a turbine having a rotor, a generator having a rated power limit, and an energy storage system, wherein the rotor generates a super-rated power above the rated power limit of the generator and the super-rated power is stored in the energy storage system before the generator converts the super-rated power into electric power.
Embodiments disclosed herein provide methods of making polymer-metal organic framework-gels (polymer-MOF-gels), the method comprising forming a metal solution comprising a metal salt, an acid, and a first solvent, and forming a product mixture comprising the metal solution, a polymer, and a carboxylic acid linker to produce the polymer-MOF-gel. Embodiments disclosed herein provide polymer-MOF-gels comprising a polymer and a metal organic framework (MOF) having pores, wherein at least a portion of the polymer is entrapped in the pores of the MOF.
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
B01J 20/281 - Sorbents specially adapted for preparative, analytical or investigative chromatography
60.
THIOL-MICHAEL ADDITION HYDROGEL-BASED BRACHYTHERAPY SYSTEM AND METHODS COMPRISING THE SAME
The invention relates generally to methods of using a thiol -Michael addition hydrogel for providing intracavitary brachytherapy and/or displacing tissue and organs. The thiol -Michael addition hydrogel may be used as a packing material and an attenuation material for intracavitary brachytherapy applications. The invention also relates generally to a brachytherapy applicator, which may be used in conjunction with the thiol -Michael addition hydrogel and methods thereof. The invention also relates to a positioning device system for providing intracavitary brachytherapy treatment and a kit thereof.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
61.
USING AN ONLINE DISTURBANCE REJECTION AND ANTICIPATION SYSTEM TO REDUCE HYPERGLYCEMIA
Embodiments relate to systems and methods for informing, determining, or controlling insulin dosage. The method involves generating plural disturbance profiles, each disturbance profile being a data representation based on historical patient data pertaining to a deviation from a threshold blood glucose level. The method involves receiving current patient data. The method involves applying a predictive model so that current patient data is compared to a disturbance profile and a probability analysis is used to assess the likelihood of a disturbance profile being an anticipated disturbance profile, the anticipated disturbance profile being a disturbance profile that is determined to match with the current patient data based on the probability analysis. The method involves determining an insulin dose amount based on the anticipated disturbance profile. The method involves outputting a signal representative of the insulin dose amount to a device configured for monitoring, influencing, and/or administering insulin levels in the patient.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A method of treating neuroinflammation in a subject, the method including administering to a subject a therapy for modulating a valeric acid-interleukin (IL)-17 pathway in the subject so that neuroinflammation in the subject is treated. The therapy administered to the subject can include exercise, fecal transplantation, an agent to decrease bacteria producing valeric acid, an agent for reducing IL-17, and/or an agent for reducing FFAR2, C3arl, C3, Iba-1, IL-1β, and/or IL-6. Such agents can include RNA interference constructs and/or antibodies. Also provided are methods for improving neurological outcome and/or mediating inflammatory response in a subject suffering from ischemic stroke and/or surgery-induced neuroinflammation.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
63.
ACOUSTIC TRAPPING MICROCHANNEL RESONANCE DETECTION AND CONTROL
A circuit implementation for on-chip real-time resonance frequency measurement and feedback control may be used to provide improved selective particle trapping. The circuit may be based on monitoring current drawn from the amplifier used to stimulate the piezo transducer, as the high impedance measurement sensitivity in this mode does not lower the power available for stimulation of the piezo transducer. The enhanced level of control of acoustic trapping using this current mode may be used for various localized channel perturbations, including drift, wash steps and buffer swaps, as well as for selective sperm cell trapping from a heterogeneous sample that includes lysed epithelial cells.
B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
B01D 43/00 - Separating particles from liquids, or liquids from solids, otherwise than by sedimentation or filtration
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
C02F 1/36 - Treatment of water, waste water, or sewage with mechanical oscillations ultrasonic vibrations
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
64.
SYSTEMS, METHODS, AND COMPUTER READABLE MEDIA FOR PARAMETRIC FDG PET QUANTIFICATION, SEGMENTATION AND CLASSIFICATION OF ABNORMALITIES
Methods, systems, and computer readable media for performing FDG positron emission tomography (PET) quantification, segmentation, and classification of abnormalities are disclosed. One method includes receiving a plurality of magnetic resonance (MR) images corresponding to a target site of a subject and generating three dimensional (3D) area masks of abnormality volumes from the plurality of MR images. The method further includes segmenting the 3D area masks into one or more individual seed images for each of the abnormality volumes and overlaying the one or more individual seed images onto co-registered parametric PET maps to generate kinetic rate parameters for each of the abnormality volumes. The method also includes utilizing the kinetic rate parameters to train a logistic regression engine to predict a target site condition assessment based on a classification of the abnormality volumes.
Provided are biomarkers for parenteral nutrition associated cholestasis (PNAC) in subjects, especially infants receiving parenteral nutrition (PN). Using such biomarkers provide methods of diagnosing and/or assessing risk of PNAC in a subject, including screening a sample from a subject believed to be at risk for PNAC for one or more biomarkers of PNAC. The biomarkers can include one or more fecal metabolites. Such biomarkers and associated methods provide neonatal intensive care unit clinicians with an additional tool for early identification of PNAC risk. Early identification of high-risk infants would enable clinicians to confidently optimize caloric nutrition with PN for infants at low risk of developing PNAC and enable proactive mitigation with alterations to the administered PN.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
G01N 33/483 - Physical analysis of biological material
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
66.
SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS
Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. The compounds can form covalent adducts with reactive nucleophilic amino acid residues, e.g., reactive tyrosines and reactive lysines, in kinases to form modified kinases and/or alter the biological activtiy of the kinases. Kinases targetable by the compounds include cyclin-dependent kinase 2 (CDK2), diacylglycerol kinases (DGKs), and phosphofructokinase (PFK). Pharmaceutical compositions including the compounds and methods of inhibiting kinases are also described.
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 413/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Provided are methods for treating Alzheimer's Disease and/or ameliorating at least one symptom thereof. In some embodiments, the methods include administering to a. subject with AD an inhibitor of a clusterin biological activity, wherein the composition is administered via a route and in an amount sufficient to inhibit the clusterin biological activity to thereby treat the subject's.AD and/or ameliorate at least one symptom thereof. Also provided are methods for reducing and/or inhibiting myelin decay in a subject in need thereof and methods for inhibiting differentiation of oligodendrocyte progenitor cells (OPCs) to mature oligodendrocytes, the method comprising contacting the OPCs with a clusterin gene product or a functional fragment or derivative thereof.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
C01B 13/14 - Methods for preparing oxides or hydroxides in general
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
69.
SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS
Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. The compounds can form covalent adducts with reactive nucleophilic amino acid residues, e.g., reactive tyrosines and reactive lysines, in kinases to form modified kinases and/or alter the biological activtiy of the kinases. Kinases targetable by the compounds include cyclin-dependent kinase 2 (CDK2), diacylglycerol kinases (DGKs), and phosphofructokinase (PFK). Pharmaceutical compositions including the compounds and methods of inhibiting kinases are also described.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
70.
STRATEGY FOR HIGHLY SUPERIOR DR5 ACTIVATION INCLUDING IN TUMORS AND CANCERS
Provided are methods for treating cancers in subjects in need thereof. In some embodiments, the methods include administering to a subject in need thereof a first composition that includes an effective amount of a binding agent that selectively binds to a tetrapeptide motif of a human CRD3 of a DR5 polypeptide and a second composition that includes an effective amount of a DR5 agonist. Also provided are methods for activating DR5 biological activities in cells, tissues, and organs, optionally cells, tissues, and organs present in subject; and compositions for use in the presently disclosed methods, including but not limited to compositions that include an effective amount of a binding agent that selectively binds to the tetrapeptide motif RKCR (SEQ ID NO: 101) of a human CRD3 of DR5 and an effective amount of a DR5 agonist and antibodies that bind to a death receptor 5 (DR5) polypeptide, including but not limited to bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
72.
SYSTEM, METHOD AND COMPUTER READABLE MEDIUM FOR DETERMINING CHARACTERISTICS OF SURGICAL RELATED ITEMS AND PROCEDURE RELATED ITEMS PRESENT FOR USE IN THE PERIOPERATIVE PERIOD
A system and method to determine characteristics of surgical related items and procedure related items present for use in the perioperative period. The system and method may apply computer vision for determining status and tracking of the surgical related items and procedure related items, as well as related clinical, logistical and operational events in the perioperative period. The system and method provides for an intuitive, automated, and transparent tracking of sterile surgical items (SSI) such as single-use, sterile surgical supplies (SUSSS) and sterile surgical instruments, and quantification of SSI waste. In doing so, the system and method empowers administrators to reduce costs and surgeons to demonstrate usage of important equipment. The system and method removes the guesswork from monitoring and minimizing SSI waste and puts the emphasis on necessity and efficiency.
A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06K 9/62 - Methods or arrangements for recognition using electronic means
73.
COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTIONS AND SIGNALING
Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, 6, 14, 16, or 18, or amino acid sequences that are about 95% identical thereto, and paratop-containing fragments thereof. Also provided are nucleic acids encoding a VH segment comprising, consisting essentially of, or consisting of SEQ ID NO: 4, a VL segment comprising, consisting essentially of, or consisting of SEQ ID NO: 16, or a combination thereof; methods for using the same to detect and/or target conformational states of FN in samples; methods for treating diseases and/or disorders and/or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
G01N 33/564 - Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease
74.
MINICELLS FROM HIGHLY GENOME REDUCED ESCHERICHIA COLI: CYTOPLASMIC AND SURFACE EXPRESSION OF RECOMBINANT PROTEINS AND INCORPORATION IN THE MINICELLS
Provided are bacterial minicells derived from genome reduced (GR) having a reduced number of expressed genes and/or is a bacterium having one or more mutated min genes. In some embodiments, the minicell has a recombinant protein present in and/or on the surface of the minicell. In some embodiments, the recombinant protein is an antigen and in some embodiments, the minicell induces an enhanced immune response against the antigen when administered to a subject. In some embodiments, the bacterium has an autotransporter (AT) expression vector encoding the recombinant protein to express the recombinant protein on the surface of the bacterium and/or the minicell derived therefrom. Also provided are vaccine compositions that include bacterial minicells, methods for producing antibodies, methods for vaccinating subjects, and expression vectors encoding heterologous proteins.
Embodiment relate to a system for developing a model to classify continuous glucose monitoring (CGM) data. The system includes a processor and computer memory having instructions stored thereon that when executed will cause the processor to determine whether two CGM profiles match based on a similarity of shapes of the two CGM profiles, each CGM profile including a data set of CGM measurements. The processor designates two matching CGM profiles as a CGM profile pair. The processor transforms the CGM profile pair into a motif. The processor labels the motif as a labelled motif based on a clinical characteristic. The processor recursively repeats the determine, designate and transform steps of a CGM profile pairing process until a finite set of motifs is created, which includes the labelled motif as a classified data point. The processor monitor, analyzes, or influences a concentration of glucose levels in a fluid.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
76.
AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIA
In one aspect, the disclosure relates to unimolecular micelles having N-hydroxysuccinimide ester (NHS), sulfo-NHS terminal groups, or other adhesive terminal groups, compositions including the same, methods of making the same, and methods of treating intimal hyperplasia in a subject using the same. In some aspects, the unimolecular micelles can further include fluorescent labels or drugs for treating intimal hyperplasia. In one aspect, the unimolecular micelles and compositions comprising the same are biocompatible, non-toxic, and non-inflammatory. In another aspect, the unimolecular micelles and compositions are substantially free from hydrogel, or are completely free from hydrogel. In still another aspect, the disclosed compositions and methods can be easily and quickly deployed in the operating room. Also disclosed is a method of applying the unimolecular micelles and compositions via direct penbrush painting.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
77.
PHOSPHINATE ESTER-CONTAINING DYES HAVING TUNABLE PROPERTIES AND METHODS OF MAKING THE SAME
In one aspect, the disclosure relates to xanthene-, thiazine-, and oxazine-based dyes containing a phosphinate ester group and having near-infrared (NIR) absorption and methods of making the same. The fluorescence lifetimes and stabilities of the dyes can be tuned by modifying the molecule cores, making them suitable for a variety of chemical labeling, imaging, and other theranostic applications. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. Exemplary compounds can form covalent adducts with reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, to form modified proteins and/or to alter the biological activity of the proteins. Pharmaceutical compositions comprising the compounds and methods of inhibiting prostaglandin reductase 2 (PTGR2) are also described. In addition, methods are described for screening proteins to identify druggable amino acid residues, e.g., druggable tyrosine and/or lysine residues.
Provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with viral infections in subjects, which in some embodiments can include administering to the subject an effective amount of a PTP4A3 inhibitor. In some embodiments, the disease, disorder, and/or condition is characterized by lung damage, ALI, ARDS, or any combination thereof. Also provided are methods for reducing or inhibiting virus-induced alveolar inflammation and/or damage, methods for reducing or inhibiting induction of inflammatory cytokines and/or chemokines in subjects, methods for reducing or inhibiting pulmonary diseases, disorders, and/or conditions associated with viral infections, or pulmonary damage resulting therefrom, methods for preventing and/or treating chemical damage to lungs, uses of PTP4A3 inhibitors in the presently disclosed methods.
Disclosed herein are anionic boron compounds. The anionic boron compounds include anionic boronic heterocycles, optionally ligated with carbenes. The anionic boron compounds are useful synthetic intermediates for boron heterocycles, as well as for sensing applications.
Provided are methods for treating and/or preventing genotoxic stress-induced cardiac toxicity, which in some embodiments include administering to a subject an effective amount of an inhibitor of t-CH, of neutrophil activation, of neutrophil migration, or any combination thereof. In some embodiments, the genotoxic stress-induced cardiac toxicity results from exposure to one or more anti-tumor and/or anti-cancer therapies, including but not limited to treatment with one or more chemotherapeutics (e.g., doxorubicin) and/or treatment with radiation. In some embodiments, the genotoxic stress-induced cardiac toxicity, the chemotherapy-induced cardiac toxicity, the chemotherapy-induced heart damage, and/or the chemotherapy-induced reduction in cardiac function is characterized by a reduction in cardiac contractility, a thinning of a ventricular wall, a reduction in cardiomyocyte size, or any combination thereof. Also provided are methods for predicting heart failure in subjects previously exposed to a genotoxic agent such as but not limited to a chemotherapeutic by detecting the presence of t-CH in the subject.
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/00 - Medicinal preparations containing organic active ingredients
82.
MAPPING INDIVIDUALIZED METABOLIC PHENOTYPE TO A DATABASE IMAGE FOR OPTIMIZING CONTROL OF CHRONIC METABOLIC CONDITIONS
in silicoin silicoin silicoin silico replay of particularized treatment scenario, and tracking over time of any divergence in one or more metabolic traits as between the subject and the digital twin to thereby detect deterioration or improvement in the subject's condition.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
83.
METHOD AND SYSTEM FOR QUANTITATIVE PHYSIOLOGICAL ASSESSMENT AND PREDICTION OF CLINICAL SUBTYPES OF GLUCOSE METABOLISM DISORDERS
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
84.
DEVELOPMENT OF COVID-19 VACCINE USING A DUAL TLR LIGAND LIPOSOME ADJUVANT
Disclosed are compositions for eliciting anti-SARS-CoV-2 immune responses in subjects. In some embodiments, the compositions include one or more SARS-CoV-2 antigens and one or more PEGylated liposomal adjuvants, wherein at least one of the PEGylated liposomal adjuvants includes a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid. Also provided are methods for using the presently disclosed compositions for stimulating anti-SARS-CoV-2 immune responses, for inducing anti- SARS-CoV-2 Thl responses, for stimulating systemic immune responses and/or mucosal immune responses, for inducing anti-SARS-CoV-2 IgA responses, for reducing SARS- CoV-2-induced lung injuries, and for inducing anti-SARS-CoV-2 neutralizing antibodies in subjects in need thereof.
Methods and systems for producing graphene from spent lithium-ion batteries are disclosed. One method includes applying an acid leaching solution to an anode of a lithium-ion battery to produce expanded graphite, applying a hydrothermal process to the expanded graphite to produce purified graphite, and subjecting the purified graphite to a shear mixing process to produce dispersed graphene. In some examples, the shear mixing process is combined with a hydrogen passivation process, which collectively improves each of graphene quality, graphene conversion rate, and graphene production efficiency.
Disclosed are phototunable hydrogels, compositions that include the same, and methods for using the same for treating wounds and/or injuries, for inhibiting formation of scar tissue at wound sites, for inhibiting fibrosis in subjects in need thereof, for inhibiting lung fibrosis and/or scarring in subject in need thereof, for inhibiting formation of myofibroblasts from fibroblasts, and for inhibiting expression of α-smooth muscle actin (α-SMA) and/or type I collagen in fibroblasts.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
87.
A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING
Disclosed is a method of modulating DNA damage response (DDR) signaling in a cell in which the modulating of DDR signaling is desired. In representative embodiments, the mehtod comprises administering to the cell an effective amount of a substance capable of modulating cyclic GMP-AMP synthase-cyclic guanosine monophosphate-adenosine monophosphate (cGAS-cGAMP) pathway activity in the cell to thereby modulate DDR signaling in the cell.
An exemplary method and system are disclosed that employ DENSE deep learning neural-network(s) trained with displacement-encoded imaging data (i.e., DENSE data) to estimate intramyocardial motion from cine MRI images and other cardiac medical imaging modalities, including standard cardiac computer tomography (CT) images, magnetic resonance imaging (MRI) images, echocardiogram images, heart ultrasound images, among other medical imaging modalities described herein. The DENSE deep learning neural-network(s) can be configured (trained) using (i) contour motion data from displacement-encoded imaging magnitude data as inputs to the neural network and (ii) displacement maps derived from displacement-encoded imaging phase images for comparison to the outputs of the neural network for neural network adjustments during the training.
Injectable fibrous hydrogel are provided. The injectable fibrous hydrogels include a guest macromer of a hyaluronic acid (HA) backbone and host macromer of a HA backbone, the guest macromer is a HA electrospun hydrogel nanofiber functionalized with adamantane (Ad), and the host macromer is a HA electrospun hydrogel nanofiber functionalized with β-cyclodextrin (CD). Injectable formulations that include the fibrous hydrogels are also provided, as are methods of making and using the same.
Provided are methods for reducing the risk of drug-related hemolysis toxicity in subjects receiving primaquine and/or tafenoquine, for improving the therapeutic index of primaquine and/or tafenoquine in subjects, and for reducing the production of reactive oxygen species in subjects receiving primaquine and/or tafenoquine. In some embodiments, the methods include co-administering an effective amount of a BlvrB inhibitor to the subjects in addition to the primaquine and/or tafenoquine. In some embodiments, the BlvrB inhibitor is one or more of phloxine B, erythrosin B, NSC130813, NSC12516, PH001924, lumichrome, PH006888, ZINC4366439/NSC 12516, xanthene, proflavine, alizarin red S, NSC ID 371876, NSC ID 179187, NSC ID 53396, NSC ID10936, NSC ID 169534, NSC ID 117269, NSC ID 143491, NSC ID 305821, NSC ID 130813, ZINC ID ZINC0977089, ZINC ID ZINC27528243, ZINC ID ZINC09330686, ZINC ID ZINC71767103, ZINC ID ZINC04160108, ZINC ID ZINC09777107, ZINC ID ZINC21093196, ZINC ID ZINC71767097, asunaprevir (BMS-650032), micafungin, tamibarotene, orantinib, sulfasalazine, febuxostat, crenolanib, olsalazine, ataluren, deferasirox, flunixin in combination with meglumin, azelastine, benzbromarone, triclabendazole, nifedipine, nisoldipine, zafirlukast, pyrantel in combination with pamoate, candesartan cilexetil, and azilsartan medoxomil.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
FRED HUTCHINSON CANCER RESEARCH CENTER (USA)
Inventor
White, Judith M.
Xu, Shuang
Schiffer, Joshua T.
Olinger, Gene G.
Finch, Courtney L.
Dyall, Julie
Abstract
Methods of modeling the in vivo efficacy of drug combinations for the treatment or prevention of viral infection are described. The described methods combine data for single drugs and drug combinations from pharmacokinetic, pharmacodynamic, and viral dynamics models under a series of estimated in vivo drug potencies to provide predictions of the in vivo effects of the drug combinations. These predictions can be used to more accurately select drugs and drug treatment regimens that can be successful in controlling viral infection in animal studies, clinical trials and in medical or veterinary interventions. Also described is a method of treating or preventing filovirus infections using combinations of orally available drugs based on predictions from the modeling methods.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Composition and methods for the modification of the secondary metabolic functions of glandular trichomes in plants, such as tobacco or cannabis, that control the formation of terpenes that impart specific flavor and aroma characteristics to the plant leaves are provided. Enhanced terpene production and composition are achieved through targeted modification in the biochemical synthesis pathways for menthol and cis-abienol. This application provides novel nucleotide sequences encoding the enzymology for production of these terpenes in tobacco and cannabis application to their use plants.
The present disclosure relates to compositions and methods related to tissue-specific promoters and their uses in plants, including tobacco and cannabis. The provided trichome-specific promoters enable the expression of heterologous polynucleotides in trichome tissues.
The present disclosure relates to compositions and methods related to modification of trichome density and transport of metabolite and their uses in plants, including tobacco and cannabis. The provided transcription factors enable the increase in trichome density in plants.
Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOs: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen Ill-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.
Some embodiments relate to therapeutic radioisotopic particles. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic particles can be in the treatment of cancer of the liver. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic radioisotope is directly coupled to a surface of a substrate of the particle.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 51/02 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier
A61K 9/00 - Medicinal preparations characterised by special physical form
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
98.
ALTERING PROTEIN FUNCTION BY PHARMACOLOGICAL TARGETING OF MEMBRANE DOMAINS
Disclosed are methods, including automated methods, for identifying a compound that impacts a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins. In some embodiments, the method comprises contacting a population of vesicles with a candidate compound, wherein a population of vesicles, wherein one or more vesicles in the population of optionally comprises one or more membrane proteins, with a candidate compound, wherein in a portion of the population of vesicles there is only a single detectable membrane phase and in a portion of the population of vesicles a membrane lipid raft phase domain and a membrane non-raft phase domain are phase separated; detecting a signal from the population of vesicles; and identifying the candidate compound as having an impact on a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins based on the signal. Systems and non- transitory computer readable medium comprising computer executable instructions embodied in a computer readable medium that when executed by a processor of a computer control the computer to perform steps of the method are also disclosed.
Provided are compositions and methods for treating and/or preventing seizure-induced death in subjects in need thereof. In some embodiments, the methods include methods for inducing an audiogenic seizure and/or seizure-induced death, treating and/or preventing death associated with seizures in subjects, preventing sudden unexpected death in epilepsy (SUDEP) in subjects, preventing and/or reducing the risk of death in subjects having SCN8A gain-of-function mutations, preventing or reducing the risk of death associated with tonic seizures in subjects, and preventing or reducing the risk of death associated with epileptic seizures in subjects. Also provided are animals that have been modified to carry gain-of-function SCN8A mutations and methods for using the same to identify compounds that have activity in treating and/or preventing seizures and/or seizure- induced death in subjects.
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.
patents
